Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older

Inclusion Criteria:

- Are 50 years of age or older on the day of screening

- Have an understanding of the study, agree to its provisions, have the ability to
adhere to the provisions of the study and give written informed consent prior to
study entry

- If female and capable of bearing children,have a negative urine pregnancy test result
within 24 hours prior to the vaccination on Study Day 0 and agree to employ adequate
birth control measures.

Exclusion Criteria:

- History of severe allergic reaction or anaphylaxis to egg protein or any other
component of the Vero cell-derived influenza vaccine or the egg-derived influenza
vaccine

- Oral temperature of >= 99.5°F (37.5°C) on the day of vaccination in this study (Note:
Subjects meeting this exclusion criterion may be rescheduled for vaccination and
study entry at a later date if certain requirements [in the study protocol] are met)

- Rash or dermatologic condition or tattoos which may interfere with injection site
reaction rating

- Blood transfusion or immunoglobulins received within 90 days of study entry

- Live vaccine received within 4 weeks or inactivated vaccine or subunit vaccine
received within 2 weeks of study entry

- Previous vaccination against influenza for the 2008/2009 northern hemisphere
influenza season

- Functional or surgical asplenia (e.g. from a history of hemoglobinopathies,
leukemias, or lymphomas)

- Diagnosed immunodeficiency as a result of a pathological condition

- Pharmacologically induced immunodeficiency as a result of prescribed administration
of corticosteroids (e.g., any systemic administration of corticosteroids or an
inhaled dose equivalent to 800 mg of beclomethasone dipropionate) or
chemotherapeutics or as a result of radiation therapy or any other modality capable
of altering normal immunologic response

- Known or suspected problem with drug or alcohol abuse

- Investigational drug received within 6 weeks prior to study entry or concurrent
participating in a clinical study that includes the administration of an
investigational product

- Subjects who are a member of the team conducting this study or are in a dependent
relationship with the study investigator. Dependent relationships include close
relatives (i.e., children, spouse/partner, siblings, parents) as well as employees of
the investigator.